AstraZeneca, Neurimmune to jointly develop cardiomyopathy drug NI006
Alexion will obtain an exclusive licence to develop, manufacture and market NI006, and will pay $30m upfront, and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
02 Mar 22
Alexion will obtain an exclusive licence to develop, manufacture and market NI006, and will pay $30m upfront, and…
16 Feb 22
ImmunoGen will receive $13m in upfront payment for initial targets and is eligible to receive an additional $32.5m…
15 Feb 22
The agreement follows the US government’s initial deal for 700,000 doses of Evusheld, which are already being administered…
08 Feb 22
Biogen will obtain exclusive global regulatory, manufacturing, and commercial rights to Xcimzane, along with the marketing authorisation
18 Jan 22
ADC Therapeutics will receive an upfront payment of $30m, and up to $205m in milestone payments, in addition…
07 Jan 22
The collaboration will use Entos’ Fusogenix nucleic acid delivery technology and Lilly's therapeutic cargo to develop nucleic acid…
30 Dec 21
Eplontersen is an investigational ligand-conjugated antisense (LICA) medicine, designed to treat all types of TTR amyloidosis (ATTR)
24 Dec 21
Under the expanded agreement, SK bioscience will reserve additional manufacturing capacity to produce antigen, a key component of…
21 Dec 21
With the latest partnership, the Swiss drugmaker intends to expand its capabilities in the research and development of…
13 Dec 21
Lilly will make an upfront payment of up to $50m to Regor, in addition to potential milestone payments…